Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Complications in Diabetic Patients

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 19, 2020

Primary Completion Date

March 29, 2022

Study Completion Date

May 4, 2022

Conditions
DiabetesHypoglycemia
Interventions
OTHER

13C-MRS procedure/Acetate infusion

Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples.

DEVICE

Continuous glucose monitoring

Participants will wear blinded continuous glucose monitoring devices (dexcom, G6) for approximately 4 weeks. Sensors will be replaced every 7-10 days.

Trial Locations (2)

70112

Tulane Medical Center, New Orleans

70808-4124

Pennington Biomedical Research Center, Baton Rouge

All Listed Sponsors
lead

Pennington Biomedical Research Center

OTHER

NCT04430660 - Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Complications in Diabetic Patients | Biotech Hunter | Biotech Hunter